Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNILAT versus Xalatan non-inferiority study in glaucoma and ocular hypertension
2007-006674-28Phase 3Completed
- Sponsor
- Unimed Pharma
- Start
- Apr 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of latanoprost in Glaucoma and ocular hypertension (2 arms), sponsored by Unimed Pharma. Primary endpoint: Primary efficacy and safety confirmation. Started Apr 2008; status: completed.
02
Drugs
latanoprost
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on 2007-006674-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006674-28.